METTL3 and neoplasm: Furthermore, Pan et al. found that nanoparticle siMETTL3 or METTL3 specific inhibitor STM2457 can elicit a profound anti-tumor immune response, and targeting m6A writer METTL3 may induce MASLD-HCC tumor regression, especially when combined with anti-PD-1 therapy [72].